Cargando…
Treatment of patients with peritoneal metastases from gastric cancer
Despite recent advances in chemotherapy, outcomes of patients with peritoneal metastases (PM) from gastric cancer are still very poor and standard treatment has not been established. Although oral S‐1 appears to be effective for patients with PM, the effects of systemic chemotherapy are limited. Cyt...
Autores principales: | Kitayama, Joji, Ishigami, Hironori, Yamaguchi, Hironori, Sakuma, Yasunaru, Horie, Hisanaga, Hosoya, Yoshinori, Lefor, Alan Kawarai, Sata, Naohiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881364/ https://www.ncbi.nlm.nih.gov/pubmed/29863151 http://dx.doi.org/10.1002/ags3.12060 |
Ejemplares similares
-
Exosomal microRNA in peritoneal fluid as a biomarker of peritoneal metastases from gastric cancer
por: Ohzawa, Hideyuki, et al.
Publicado: (2019) -
CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model
por: Tsukui, Hidenori, et al.
Publicado: (2020) -
Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer
por: Takahashi, Kazuya, et al.
Publicado: (2022) -
Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases
por: Saito, Shin, et al.
Publicado: (2020) -
Reduced expression of exosomal miR-29s in peritoneal fluid is a useful predictor of peritoneal recurrence after curative resection of gastric cancer with serosal involvement
por: Ohzawa, Hideyuki, et al.
Publicado: (2020)